CLAIMS

1. A compound of formula (I)



formula (I)

where

R^1 is selected from a hydrogen atom, a halogen atom, a cyano group, a C_1-C_3-alkyl group, a C_1-C_3-haloalkyl group, and a C_1-C_3-haloalkoxy group;

R^2 is selected from a hydrogen atom and a halogen atom;

R^3 is selected from,

a C_1-C_6-alkyl group which is optionally substituted with one or two substituents and each substituent is independently selected from a hydroxy group, a C_1-C_4-alkoxy group and a 3- to 7-membered heterocycloalkyl group;

a C_2-C_6-alkenyl group which is optionally substituted with an C_1-C_4-alkoxy group;

a C_3-C_9-cycloalkyl group, which is optionally substituted with a hydroxy group;

a C_5-C_9-cycloalkenyl group, which is optionally substituted with a hydroxy group;

a 3- to 9-membered heterocycloalkyl group, comprising one, two or three heteroatoms which are independently selected from –O-, -S-, -S(O)-, $S(O)_2$, and-NR^9-,

and said heterocycloalkyl group optionally further comprising a bridging group selected from –O-, -NR^9-, -CH_2-, -CH_2-CH_2-, -O-CH_2-, -CH_2-O-, -NR^9-CH_2-, and -CH_2-NR^9-;

and said heterocycloalkyl group is optionally substituted with one, two or three substituents and each substituent is independently selected from

a halogen atom;

a oxo(=O) group;

a cyano group;

a hydroxy group;

a C_1-C_3-alkyl group which is optionally further substituted with a hydroxy group;

a C_1-C_3-haloalkyl group;

a C_1-C_3-alkoxy group;

a C_1-C_3-haloalkoxy group;

a $C(O)NR^5R^6$ group

and a NR^5R^6 group;

a 5- to 9-membered heterocycloalkyl group which is partially unsaturated and optionally substituted with one, two or three substituents and each substituent is independently selected from an oxo group (=O), a C_1-C_3-alkyl group, a $-C(O)R^5R^6$ group and a halogen atom;

an aryl group which is optionally substituted with one, two, three or four substituents and each substituent is independently selected from a halogen atom, a hydroxy group, a cyano group, a C_1-C_3-alkyl group, a C_1-C_3-haloalkyl group, a C_1-C_3-alkoxy group, a C_1-C_3-haloalkoxy group, and a NR^5R^6 group;

a mono- or bicyclic heteroaryl group which is optionally substituted with one, two or three substituents and each substituent is independently selected from a halogen atom, a C_1-C_3-alkyl group, a cyano group, a C_1-C_3-haloalkyl group, a C_1-C_3-hydroxalkyl group, a C_1-C_3-alkoxy group, a hydroxy group, and a NR^5R^6 group, with the proviso that said monocyclic heteroaryl group is not 4-pyridyl;

and a NR^7R^8 group;

R^4 is selected from a hydrogen atom, and a C_1-C_3-alkyl group;

R^5 /R^6 are independently selected from a hydrogen atom, a C_1-C_6-alkyl group, a -C_1-C_5-alkylene-O-C_1-C_5-alkyl group, a -C_1-C_5-alkylene-S-C_1-C_5-alkyl group, C_3-C_6-cycloalkyl group, and a C_3-C_5-heterocycloalkyl group;

R^7 /R^8 are independently selected from a hydrogen atom, with the proviso that R^7 = R^8 = hydrogen is excluded,

a C_1-C_6-alkyl group,

which is optionally substituted with one, two, three or four substituents and said substituent is independently selected from

a halogen atom,

a cyano group,

a hydoxy group,

a $C(O)NR^5R^6$ group,

a NR^5R^6 group,

a C_1-C_3-alkoxy group,

a C_3-C_7-cycloalkyl group which is optionally substituted with one or two substitutents and said subtituents are independently selected from a C_1-C_3-alkyl group, a oxo (=O) group, a hydroxy group, and a C_1-C_3-hydroxyalkyl group;

a 3- to 7-membered heterocycloalkyl group which itself is optionally substituted with, a C_1-C_3-alkyl group or an oxo (=O) group;

a heteroaryl group, which itself is optionally substituted with a C_1-C_3-alkyl group;

a -C_1-C_5-alkylene-O-C_1-C_5-alkyl group;

a -C_1-C_5-alkylene-S-C_1-C_5-alkyl group;

a -C_1-C_5-alkylene-NR^5-C_1-C_5-alkyl group;

a C_3-C_6-cycloalkyl group which is optionally substituted with a hydroxy group; and

a 3- to 6-membered heterocycloalkyl group, which is optionally substituted with one or two substituents, said substituent independently selected from C_1-C_3-alkyl group and a hydroxy group;

R^9 is a hydrogen atom or a C_1-C_3-alkyl group or a bond;

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

2. The compound according to claim 1,

where

R^1 is selected from a hydrogen atom, a halogen atom, a cyano group, a C_1-C_3-alkyl group, a C_1-C_3-haloalkyl group , and a C_1-C_3-haloalkoxy group;

R^2 is selected from a hydrogen atomand a halogen atom;

R^3 is selected from

a C_1-C_6-alkyl group which is optionally substituted with a substituent which is selected from a hydroxy group, a C_1-C_4-alkoxy group, and a 3- to 7-membered heterocycloalkyl group;

a C_2-C_6-alkenyl group which is optionally substituted with an C_1-C_4-alkoxy group;

a C_3-C_7-cycloalkyl group, which is optionally substituted with a hydroxy group;

a C_5-C_7-cycloalkenyl group, which is optionally substituted with a hydroxy group;

a 3- to 7-membered-heterocycloalkyl group, comprising one, or two heteroatoms which are independently selected from –O-, $S(O)_2$, and -NR^9-,

and said heterocycloalkyl group is optionally substituted with one, or two substituents and each substituent is independently selected from

a halogen atom;

a cyano group;

a hydroxy group;

a C_1-C_3-alkyl group which is optionally further substituted with a hydroxy group;

a C_1-C_3-alkoxy group;

a $C(O)NR^5R^6$ group and

a NR^5R^6 group;

a 5- to 7-membered-heterocycloalkyl group, comprising a heteroatom which is selected from –O-, -S- and -NR^9-, which is partially unsaturated and optionally substituted with a substituent which is selected from a C_1-C_3-alkyl groupand a halogen atom;

an aryl group which is optionally substituted with one, two, or three substituents and each substituent is independently selected from a halogen atom, a hydroxy group, a cyano group, a C_1-C_3-alkyl group, a C_1-C_3-haloalkyl group, a C_1-C_3-alkoxy group, and a NR^5R^6 group;

a mono- or bicyclic heteroaryl group which is optionallysubstituted with a substituent which is selected from a halogen atom, a C_1-C_3-alkyl group, a cyano group, a C_1-C_3-haloalkyl group, a C_1-C_3-alkoxy group, and a NR^5R^6 group, with the proviso that said monocyclic heteroaryl group is not a pyridin-4-yl group;

and a NR^7R^8 group;

R^4 is selected from a hydrogen atom, and a C_1-C_3-alkyl group;

R^5 /R^6 are independently selected from a hydrogenatom and a C_1-C_6-alkyl group;

R^7 /R^8 are independently selected from

a hydrogen atom, with the proviso that R^7 = R^8 = hydrogen is excluded,

a C_1-C_6-alkyl group, which is optionally substituted with one, two, three or foursubstituents and said substituent is independently selected from

a halogen atom;

a cyano group;

a hydroxy group;

a C(O)NR^5R^6 group;

a NR^5R^6 group;

a C_1-C_3-alkoxy group;

a C_3-C_7-cycloalkyl groupwhich is optionally further substituted with one or two substituentsand said substituents are independently selected from a C_1-C_3-alkylgroup, a oxo (=O) group, a hydroxy group, and a C_1-C_3-hydroxyalkyl group;

a 3- to 7-membered heterocycloalkyl group , comprising one, two or three heteroatoms which are independently selected from –O- and -NR^9-, which is optionally further substituted with a C_1-C_3-alkyl group;

a heteroaryl group, which is optionally further substituted with a C_1-C_3-alkyl group;

a C_3-C_7-cycloalkyl group which is optionally substituted with a hydroxy group, or a C_1-C_3-alkyl group and

a 3- to 6-membered heterocycloalkyl group, which is optionally substituted with one or two substituents, said substituent independently selected from C_1-C_3-alkyl group and a hydroxy group;

R^9 is a hydrogen atom or a C_1-C_3-alkyl group or a bond;

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

3. The compound according to claim 1,

where

R^1 is selected from a hydrogen atom, a halogen atom, a C_1-C_3-alkyl grou, a C_1-C_3-haloalkyl group, and a C_1-C_3-haloalkoxy group;

R^2 is selected from a hydrogen atom and a halogen atom;

R^3 is selected from,

a C_1-C_6-alkyl group which is optionally substituted with a substituent which is selected from a hydroxy group, a C_1-C_4-alkoxy group, and a 3- to 7-membered heterocycloalkyl group;

a C_2-C_6-alkenyl group which is optionally substituted with an C_1-C_4-alkoxy group;

a C_3-C_7-cycloalkyl group, which is optionally substituted with a hydroxy group;

a C_5-C_7-cycloalkenyl group;

a 3- to 7-membered heterocycloalkyl group, comprising one, or two heteroatoms which are independently selected from –O-, and -NR^9-,

and said heterocycloalkyl group is optionally further substituted with one, or two substituents and each substituent is independently selected from

a halogen atom;

a cyano group;

a hydroxy group;

a C_1-C_3-alkyl group which is optionally further substituted with a hydroxy group;

a C_1-C_3-alkoxy group and

a C(O)NR^5R^6 group;

a 5- to 7-membered-heterocycloalkyl group, comprising a heteroatom which is selected from –O-, and -NR^9-, which is partially unsaturated and optionally substituted with a substituent which is selected from a C_1-C_3-alkyl group and a halogen atom,

an aryl group which is optionally substituted with one, two, or three substituents and each substituent is independently selected from a halogen atom, a hydroxy group, a cyano group, a C_1-C_3-alkyl group, a C_1-C_3-haloalkyl group, and a NR^5R^6 group;

a mono- or bicyclic heteroaryl group which is optionally substituted with a substituent which is selected from a halogen atom, a C_1-C_3-alkyl groupa C_1-C_3-haloalkyl group, a C_1-C_3-alkoxy group, and a NR^5R^6 group, with the proviso that said monocyclic heteroaryl group is not a pyridin-4-yl group;

and a NR^7R^8 group;

R^4 is selected from a hydrogen atom, and a C_1-C_3-alkyl group;

R^5 /R^6 are independently selected from a hydrogen atom and a C_1-C_6-alkyl group;

R^7 /R^8 are independently selected from

a hydrogen atom, with the proviso that R^7 = R^8 = hydrogen is excluded,

a C_1-C_6-alkyl group, which is optionally substituted with one, two, three or four substituents and said substituent is independently selected from

a halogen atom;

a cyano group;

a hydroxy group;

a NR^5R^6 group;

a C_1-C_3-alkoxy group;

a C_3-C_7-cycloalkyl group which is optionally further substituted with one or two substituents and said substituents are independently selected from a C_1-C_3-alkyl group, a oxo (=O) group, a hydroxy group, and a C_1-C_3-hydroxyalkyl group;

a 3- to 7-membered heterocycloalkyl group, comprising one, two or three heteroatoms which are independently selected from –O- and -NR^9-, which is optionally further substituted with a C_1-C_3-alkyl group;

a heteroaryl group, which is optionally further substituted with a C_1-C_3-alkyl group;

a C_3-C_7-cycloalkyl group which is optionally substituted with a hydroxy group, or a C_1-C_3-alkyl group and

a 3- to 6-membered heterocycloalkyl group, which is optionally substituted with one or two substituents, said substituent independently selected from C_1-C_3-alkyl group and a hydroxy group;

R^9 is a hydrogen atom or a C_1-C_3-alkyl group or a bond;

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

4. The compound according to claim 1,

where

R^1 is selected from a hydrogen atom, a halogen atom , a C_1-C_3-alkyl group, a C_1-C_3-haloalkyl group, and a C_1-C_3-haloalkoxy group;

R^2 is selected from a hydrogen atom and a halogen atom;

R^3 is selected from,

a C_1-C_6-alkyl group which is optionally substituted with a substituent which is selected from a hydroxy group, a C_1-C_4-alkoxy group and a a 3- to 7-membered heterocycloalkyl group;

a C_2-C_6-alkenyl group which is optionally substituted with an C_1-C_4-alkoxy group;

a C_4-C_6-cycloalkyl group, which is optionally substituted with a hydroxy group;

a C_5-C_7-cycloalkenyl group;

a 3- to 6-membered heterocycloalkyl group, comprising one, or two heteroatoms which are independently selected from –O-, and -NR^9-,

and said heterocycloalkyl group is optionally further substituted with one, or two substituents and each substituent is independently selected from

a halogen atom;

a cyano group;

a hydroxy group;

a C_1-C_3-alkyl group which is optionally further substituted with a hydroxy group;

a 5- to 6-membered-heterocycloalkyl group, comprising a heteroatom which is selected from –O-, and -NR^9-, which is partially unsaturated and optionally substituted with a substituent which is selected from a C_1-C_3-alkyl group and a halogen atom;

an aryl group which is optionally substituted with one, or two, substituents and each substituent is independently selected from a halogen atom, a hydroxy group, a cyano group, a C_1-C_3-alkyl group, a C_1-C_3-haloalkyl group, and a NR^5R^6 group;

a mono- or bicyclic heteroaryl group which is optionally substituted with a substituent which is selected from a halogen atom, a C_1-C_3-alkyl group a C_1-C_3-haloalkyl group, a C_1-C_3-alkoxy group, and a NR^5R^6 group, with the proviso that said monocyclic heteroaryl group is not a pyridin-4-yl group;

and a NR^7R^8 group;

R^4 is selected from a hydrogen atom, and a C_1-C_3-alkyl group;

R^5 /R^6 are independently selected from a hydrogen atom and a C_1-C_6-alkyl group;

R^7 /R^8 are independently selected from

a hydrogen atom, with the proviso that R^7 = R^8 = hydrogen is excluded,

a C_1-C_6-alkyl group, which is optionally substituted with one, two, three or four substituents and said substituent is independently selected from

a halogen atom;

a hydroxy group;

a C_1-C_3-alkoxy group;

a C_3-C_6-cycloalkyl group which is optionally further substituted with one or two substituents and said substituents are independently selected from a C_1-C_3-alkyl group and a C_1-C_3-hydroxyalkyl group;

a 4- to 6-membered heterocycloalkyl group, comprising one, two or three heteroatoms which are independently selected from –O- and -NR^9-, which is optionally further substituted with a C_1-C_3-alkyl group;

a heteroaryl group, which is optionally further substituted with a C_1-C_3-alkyl group;

a C_3-C_6-cycloalkyl group which is optionally substituted with a hydroxy group, or a C_1-C_3-alkyl group;

a 3- to 6-membered heterocycloalkyl group, which is optionally substituted with one or two substituents, said substituent independently selected from C_1-C_3-alkyl group and a hydroxy group, and

R^9 is a hydrogen atom or a C_1-C_3-alkyl group or a bond;

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

5. The compound according to claim 1,

where

R^1 is selected from a hydrogen atom, a halogen atom , a C_1-C_3-alkyl group, and a C_1-C_3-haloalkyl group ;

R^2 is selected from a hydrogen atom and a halogen atom;

R^3 is selected from,

a C_1-C_6-alkyl group which is optionally substituted with one or two substituents and each substituent is independently selected from a hydroxy group, a C_1-C_4-alkoxy group, and a 3- to 7-membered heterocycloalkyl group;

a C_2-C_6-alkenyl group which is optionally substituted with an C_1-C_3-alkoxy group;

a C_3-C_7-cycloalkyl group, which is optionally substituted with a hydroxy group ;

a C_5-C_6-cycloalkenyl group, which is optionally substituted with a hydroxy group;

a 3- to 6-membered heterocycloalkyl group, comprising one, two or three heteroatoms which are independently selected from –O- and-NR^9-,

and said heterocycloalkyl group is optionally substituted with one, two or three substituents and each substituent is independently selected from

a halogen atom;

a oxo(=O) group;

a cyano group;

a hydroxy group;

a C_1-C_3-alkyl group which is optionally further substituted with a hydroxy group;

a 5- to 7-membered heterocycloalkyl group which is partially unsaturated and optionally substituted with one or two substituents and each substituent is independently selected from a C_1-C_3-alkyl group and a halogen atom;

an aryl group which is optionally substituted with one, two, three or four substituents and each substituent is independently selected from a halogen atom, a hydroxy group, a cyano group, a C_1-C_3-alkyl group, a C_1-C_3-haloalkyl group, a C_1-C_3-alkoxy group, a C_1-C_3-haloalkoxy group, and a NR^5R^6 group;

a mono- or bicyclic heteroaryl group which is optionally substituted with one or two substituents and each substituent is independently selected from a halogen atom, a C_1-C_3-alkyl group, a cyano group, a C_1-C_3-haloalkyl group, a C_1-C_3-alkoxy group, a hydroxy group, and a NR^5R^6 group, with the proviso that said monocyclic heteroaryl group is not a pyridin-4-yl group;

and a NR^7R^8 group;

R^4 is selected from a hydrogen atom, and a C_1-C_3-alkyl group;

R^5 /R^6 are independently selected from a hydrogen atom and a C_1-C_6-alkyl group;

R^7 /R^8 are independently selected from

a hydrogen atom, with the proviso that R^7 = R^8 = hydrogen is excluded,

a C_1-C_6-alkyl group,

which is optionally substituted with one, two, three or four substituents and said substituent is independently selected from

a halogen atom,

a cyano group,

a hydoxy group,

a C_1-C_3-alkoxy group,

a C_3-C_7-cycloalkyl group which is optionally substituted with one or two substitutents and said subtituents are independently selected from a C_1-C_3-alkyl group, a hydroxy group, and a C_1-C_3-hydroxyalkyl group;

a 3- to 7-membered heterocycloalkyl group which itself is optionally substituted with a C_1-C_3-alkyl group;

and a heteroaryl group, which is optionally further substituted with a C_1-C_3-alkyl group;

a C_3-C_6-cycloalkyl group which is optionally substituted with a hydroxy group, and

a 3- to 6-membered heterocycloalkyl group,which is optionally substituted with one or two substituents said substituent independently selected from C_1-C_3-alkyl group and a hydroxy group,

R^9 is a hydrogen atom or a C_1-C_3-alkyl group or a bond;

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

6. The compound according to claim 1,

where

R^1 is selected from a hydrogen atom, a halogen atom , a C_1-C_3-alkyl group, and a C_1-C_3-haloalkyl group ;

R^2 is selected from a hydrogen atom and a halogen atom;

R^3 is selected from,

a 3- to 6-membered heterocycloalkyl group, comprising one, or two heteroatoms which are independently selected from –O-, and -NR^9-,

and said heterocycloalkyl group is optionally further substituted with one, or two substituents and each substituent is independently selected from

a halogen atom;

a hydroxy group;

and a C_1-C_3-alkyl group which is optionally further substituted with a hydroxy group;

an aryl group which is optionally substituted with one, or two, substituents and each substituent is independently selected from a halogen atom, a hydroxy group, and a C_1-C_3-haloalkyl group;

a mono- or bicyclic heteroaryl group which is optionally substituted with a substituent which is selected from a halogen atom, a C_1-C_3-alkyl group a C_1-C_3-haloalkyl group and a NR^5R^6 group, with the proviso that said monocyclic heteroaryl group is not a pyridin-4-yl group;

and a NR^7R^8 group;

R^4 is selected from a hydrogen atom, and a C_1-C_3-alkyl group;

R^5 /R^6 are independently selected from a hydrogen atom and a C_1-C_3-alkyl group;

R^7 /R^8 are independently selected from

a hydrogen atom, with the proviso that R^7 = R^8 = hydrogen is excluded,

a C_1-C_6-alkyl group, which is optionally substituted with one or two, three or four substituents and said substituent is independently selected from

a halogen atom;

a hydroxy group;

a C_1-C_3-alkoxy group;

a C_3-C_5-cycloalkyl group which is optionally further substituted with one or two substituents and said substituents are independently selected from a C_1-C_3-alkyl group and a C_1-C_3-hydroxyalkyl group;

a 5- to 6-membered heterocycloalkyl group, comprising one, or two heteroatoms which are independently selected from -O- and -NR^9-, which is optionally further substituted with a C_1-C_3-alkyl group,

a heteroaryl group, which is optionally further substituted with a C_1-C_3-alkyl group;

a C_3-C_6-cycloalkyl group which is optionally substituted with a hydroxy group, or a C_1-C_3-alkyl group;

a 4- to 5-membered heterocycloalkyl group, which is optionally substituted with one or two substituents, said substituent independently selected from C_1-C_3-alkyl group and a hydroxy group; and

R^9 is a hydrogen atom or a C_1-C_3-alkyl group or a bond;

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

7. The compound according to claim 1,

where

R^1 is selected from CF_3 and a fluorine atom;

R^2 is a hydrogen atom;

R^3 is selected from

an aryl group which is optionally substituted with a substituent which is selected from a halogen atom and a C_1-C_3-haloalkyl group,

a monocyclic heteroaryl group substituted with a substituent which is selected from C_1-C_3-haloalkyl group and NR^5R^6 group;

and a NR^7R^8 group;

R^4 is selected from a hydrogen atom and a methyl group;

R^5 /R^6 are independently selected from a hydrogen atom and a methyl group;

R^7 /R^8 are independently selected from

a hydrogen atom, with the proviso that R^7 = R^8 = hydrogen is excluded,

a C_1-C_3-alkyl group, which is optionally substituted with one, two or four substituents and said substituent is independently selected from

a halogen atom, a hydroxy group, and a methoxy group,

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

8. The compound according to claim 1, which is selected from the group consisting of:

5-[4-(4,4-difluoropiperidin-1-yl)-3-fluorophenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-chloro-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4'-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-fluoro-4-(morpholin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-fluoro-4-(4-fluoro-4-methylpiperidin-1-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-fluoro-4-(4-fluoropiperidin-1-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(4'-fluoro-2-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(3',4'-difluoro-2-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(4'-fluoro-2,2'-dimethylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(3,6-dihydro-2H-pyran-4-yl)-3-methylphenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-methyl-4-(1H-pyrazol-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-methyl-4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-methyl-4-(pyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-methyl-4-(pyrimidin-5-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(3'-fluoro-2-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

(rac)-6-methyl-5-(3,4,5-trifluorophenyl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

(rac)-5-[3,5-difluoro-4-(morpholin-4-yl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

(rac)-5-{3,5-difluoro-4-[-2-methylmorpholin-4-yl]phenyl}-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

(rac)-5-(4-bromophenyl)-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one

(rac)-6-methyl-5-[4-(morpholin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3,5-difluoro-4-(morpholin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

2-(morpholin-4-yl)-5-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)benzonitrile,

3-chloro-2-(morpholin-4-yl)-5-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)benzonitrile,

5-{4-[2,6-dimethylmorpholin-4-yl]-3-fluorophenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

(6S)-5-(3-Fluoro-4-morpholinophenyl)-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

(6S)-5-(3,5-Difluoro-4-morpholinophenyl)-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(3,3-difluoropyrrolidin-1-yl)-3-fluorophenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-methyl-4-(2-methylpyrimidin-5-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-methyl-4-(1-methyl-1H-pyrazol-5-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2,4'-difluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4'-chloro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(6-methylpyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(pyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4'-amino-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3'-hydroxy-4'-methyl-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-{3-(trifluoromethyl)-4-[6-(trifluoromethyl)pyridin-3-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4'-fluoro-3'-hydroxy-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[5'-amino-2',4'-difluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4'-amino-3'-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(6-aminopyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3'-amino-4'-chloro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3'-amino-4'-methyl-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3'-amino-2'-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4'-amino-2'-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(1-methyl-1H-pyrazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(3-methyl-1H-pyrazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(1H-indazol-6-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(5-fluoro-6-methylpyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(1,2-thiazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

1-methyl-5-[4-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]-1H-pyrrole-2-carbonitrile,

5-[2,4'-bis(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(1,3-dimethyl-1H-pyrazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(2-methoxy-6-methylpyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(2-methyl-1,3-thiazol-5-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4'-(methylamino)-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3'-amino-4'-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-fluoro-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3',4',5'-trifluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[2',5'-difluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3'-amino-4'-fluoro-2-(trifluoromethoxy)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3',4'-difluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(1H-indol-6-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(2-methylprop-1-en-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[2',3'-difluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(morpholin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(butylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(ethylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(1-methyl-1H-pyrazol-4-yl)-3-(trifluoromethoxy)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(propylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(6-methylpyridin-3-yl)-3-(trifluoromethoxy)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4'-chloro-2-(trifluoromethoxy)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(azetidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(1-methyl-1H-benzimidazol-6-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(pentylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(1-methyl-1H-indazol-6-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4'-fluoro-2-(trifluoromethoxy)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-fluoro-4-(6-fluoropyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-fluoro-4-(3-methylpyridin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-fluoro-4-(2-methylpyridin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(4'-amino-2-fluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2-fluoro-2'-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2'-chloro-2,4'-difluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(cyclopent-1-en-1-yl)-3-fluorophenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2'-ethyl-2-fluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-fluoro-4-(6-methoxypyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2,4'-difluoro-3'-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2-fluoro-3'-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2-fluoro-4'-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2-fluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(2-aminopyridin-4-yl)-3-fluorophenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(3'-amino-2-fluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4'-(difluoromethyl)-2-fluorobiphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-fluoro-4-(2-methylpyrimidin-5-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-fluoro-4-(2-methoxypyridin-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-fluoro-4-(2-methylpyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-fluoro-4-(6-methylpyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2,2',4',5'-tetrafluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2,2',3',4'-tetrafluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2,2',5'-trifluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

2'-fluoro-4'-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)biphenyl-4-carbonitrile,

5-(2'-amino-2-fluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(3'-amino-2-fluoro-4'-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2-fluoro-3'-hydroxybiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2-fluoro-4'-hydroxybiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2-fluoro-2'-hydroxybiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2,3',4'-trifluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-fluoro-4-(pyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2,2',3'-trifluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2,3',5'-trifluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2,2',4'-trifluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2-fluoro-2',4'-dimethylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2,3'-difluoro-4'-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2,2'-difluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2,2',6'-trifluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2-fluoro-2'-methoxybiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(2,3'-difluorobiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[3-fluoro-4-(4-methylpyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

(rac)-5-(3-Fluoro-4-morpholinophenyl)-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

(6S)-6-methyl-5-[4-(morpholin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

(6*S*)-5-(-[(3-chloro-4--(morpholin-4-yl)-5-(trifluoromethyl)phenyl-)]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

6*S*)-5-(-[(4-chloro-3-(trifluoromethyl)phenyl-)]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-(-[(4-fluoro-3-(trifluoromethyl)phenyl-)]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-chloro-3-(trifluoromethoxy)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-(4-chloro-3-methylphenyl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

(rac)-6-methyl-5-(4-morpholino-3-(trifluoromethyl)phenyl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(3,5-dimethyl-1H-pyrazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(3,5-dimethyl-1,2-oxazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{3-(trifluoromethyl)-4-[3-(trifluoromethyl)-1H-pyrazol-4-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(1-ethyl-1H-pyrazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[cyclopentyl(methyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[butyl(methyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-[4'-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(cyclopentylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[3'-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-methyl-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-{4-[3-methoxyprop-1-en-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(rac)-5-[4'-hydroxy-2-(trifluoromethyl)-2',3',4',5'-tetrahydro[1,1'-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(5,6-dihydro-2H-pyran-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(imidazo[1,2-a]pyridin-6-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[3,3-dimethylbut-1-en-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{3-(trifluoromethyl)-4-[5-(trifluoromethyl)thiophen-3-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(prop-1-en-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(1-benzothiophen-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(2,5-dihydrofuran-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(cyclopent-1-en-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(1-ethyl-1H-imidazol-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
3-methyl-5-[4-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]thiophene-2-carbonitrile,
5-{4-[1-(propan-2-yl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(rac)-5-[4-(bicyclo[2.2.1]hept-2-en-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[2'-fluoro-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{3-(Trifluoromethyl)-4-[5-(trifluoromethyl)thiophen-2-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(5-methylpyridin-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-(5-fluoropyridin-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(5-chloropyridin-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(pyridin-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[2'-(Difluoromethyl)-2-fluoro[1,1'-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-(2,4'-Difluoro-2'-methyl[1,1'-biphenyl]-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
2'-fluoro-2-methyl-4'-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)[1,1'-biphenyl]-4-carbonitrile,
5-[4-(2-Methylprop-1-en-1-yl)-3-(trifluoromethoxy)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-[4-(2-aminopyridin-4-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-6-methyl-5-[4-(6-methylpyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-[2'-fluoro-4'-methyl-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-6-methyl-5-[2',4',5'-trifluoro-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-[2',5'-difluoro-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
4'-[(6S)-6-methyl-2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl]-2'-(trifluoromethyl)[1,1'-biphenyl]-2-carbonitrile,
(6S)-5-[4-(1H-indol-5-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-[4'-hydroxy-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-[3'-hydroxy-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-[3'-amino-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-[2',4'-difluoro-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

(6S)-5-[3'-fluoro-4'-methyl-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-[2'-fluoro-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-[2'-methoxy-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-[3'-fluoro-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-6-methyl-5-[4-(4-methylpyridin-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-6-methyl-5-[4-(3-methylpyridin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-6-methyl-5-[4-(2-methylpyridin-4-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-[4-(1H-indol-6-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-[4-(6-methoxypyridin-3-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-[4'-methoxy-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-6-methyl-5-[4'-methyl-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-{4-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)-phenyl}-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)-phenyl}-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4'-fluoro-2-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3-fluoro-5-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{3-(difluoromethyl)-4-[1-(difluoromethyl)-1H-pyrazol-4-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-6-methyl-5-{4-[(morpholin-4-yl)methyl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[(morpholin-4-yl)methyl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[2-(difluoromethyl)-4'-fluoro[1,1'-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4'-chloro-2-(difluoromethyl)[1,1'-biphenyl]-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[3-(difluoromethyl)-4-(6-methylpyridin-3-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(cyclopent-1-en-1-yl)-3-(difluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[3-(difluoromethyl)-4-(1H-pyrazol-4-yl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(3-Hydroxy-3-methylazetidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(rac)-5-[4-{[3,3,3-trifluoro-2-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[(Oxan-4-yl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-{[(cis/trans)-3-hydroxycyclobutyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[(rac)-2,4-Dimethylazetidin-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[(cis or trans)-2,4-Dimethylazetidin-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-{[3,3,3-Trifluoro-2(S)-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[(2-Hydroxy-2-methylpropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-{[(trans)-4-Hydroxycyclohexyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[(Cyclopropylmethyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-{[(3-Methyloxetan-3-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
-{4-[(3-Methoxypropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-({[(rac)-Oxolan-2-yl]methyl}amino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-[4-{[2(R)-2-Hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-{[(3R)-3-Hydroxybutyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-{[(2S)-2-Hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-{[(1-Hydroxycyclobutyl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[(3-Methylbutyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[(2-Methylpropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[(2-Methoxyethyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[Ethyl(methyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(tert-butylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-({[(2R)-oxolan-2-yl]methyl}amino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-{[(pyrazin-2-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(4-hydroxypiperidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-{[(2S)-1-hydroxybutan-2-yl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(3-hydroxypiperidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one (racemic mixture),
(rac)-1-[4-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]piperidine-3-carboxamide ,
5-{4-[(3-hydroxy-2,2-dimethylpropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(4,4-difluoropiperidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-{[(1R,2R,4R)-bicyclo[2.2.1]heptan-2-yl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-{4-[(3S)-3-hydroxypyrrolidin-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(rac)-5-{4-[(2-hydroxy-3-methoxypropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-{[(1-methyl-1H-pyrazol-5-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-{[(1H-pyrazol-3-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-{[2-(1H-pyrazol-1-yl)ethyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
1-[4-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]piperidine-4-carbonitrile,
(rac)-5-{4-[(1-cyclopropylethyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one ,
(rac)-5-{4-[(2-ethoxypropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one
(rac)-5-{4-[(2-methoxypropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one
5-[4-(3-ethoxyazetidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-{[(pyrimidin-2-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-{[(oxolan-3-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one (racemic mixture),
5-[4-{[(2S)-4-hydroxybutan-2-yl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(rac)-5-[4-{[(6-oxopiperidin-3-yl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(rac)-5-[4-{[(2,2-dimethylcyclopropyl)methyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-({[1-(hydroxymethyl)cyclobutyl]methyl}amino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[(2S)-2-(hydroxymethyl)azetidin-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
3-methyl-1-[4-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]azetidine-3-carbonitrile,

5-[4-(3-azabicyclo[3.1.0]hexan-3-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(4-ethyl-4-hydroxypiperidin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
4-[4-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)anilino]butanenitrile,
6-[4-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoro-methyl)phenyl]-2lambda^6-thia-6-azaspiro[3.3]heptane-2,2-dione,
N^2-[4-(2-oxo-3,6-dihydro-2H-1,3,4-oxadiazin-5-yl)-2-(trifluoromethyl)phenyl]glycinamide,
5-{4-[(3R)-3-hydroxypyrrolidin-1-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[(2-methoxy-2-methylpropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one
5-[4-({[(2S)-oxolan-2-yl]methyl}amino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[(2-ethoxyethyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-{[(1S,2R)-2-hydroxycyclopentyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[(oxetan-3-yl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-on,
5-{3-(difluoromethyl)-4-[1-(propan-2-yl)-1H-pyrazol-4-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[3-fluoro-4-(morpholin-4-yl)-5-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-6-methyl-5-{3-(trifluoromethyl)-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-6-methyl-5-{3-(trifluoromethyl)-4-[4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(3-Methoxypropyl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(2-methylpropyl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(3,3-dimethylbutyl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(Propan-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

(rac)-5-{4-[oxan-3-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one ,
(trans)-5-{4-[4-hydroxycyclohexyl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one (trans isomer),
(cis)-5-{4-[4-hydroxycyclohexyl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one ,
5-{4-[(2-Aminoethyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one— salt with hydrochloric acid ,
5-{4-[1-amino-3-azabicyclo[3.1.0]hexan-3-yl]-3-(trifluoromethyl)-phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one—salt with hydrochloric acid,
5-[4-(methylamino)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-6-methyl-5-[4-(4-methylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-(2-hydroxypropan-2-yl)-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-[4-(3,3-difluoroazetidin-1-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one, and
(6S)-5-[4-(3-hydroxy-3-methylazetidin-1-yl)-3-(trifluoromethyl)-phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

9. A compound according to claim 8 which is selected from the group consisting of:
5-[4'-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-(4'-fluoro-2-methylbiphenyl-4-yl)-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4'-chloro-2-(trifluoromethyl)biphenyl-4-yl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-{4-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)-phenyl}-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-[4-{[3,3,3-Trifluoro-2(S)-hydroxypropyl]amino}-3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[(2-Hydroxy-2-methylpropyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
5-{4-[(2-Methoxyethyl)amino]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
(6S)-5-[4'-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

5-{4-[1-(difluoromethyl)-1H-pyrazol-4-yl]-3-(trifluoromethyl)phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

(6S)-5-[4-(2-aminopyridin-4-yl)-3-(trifluoromethyl)phenyl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one, and

(6S)-6-methyl-5-{3-(trifluoromethyl)-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,

or a stereoisomer or a salt thereof, or a mixture of same.

10. A method of preparing a compound of general formula (I) according to any one of claims 1 to 9, said method comprising

EITHER

the step A of allowing an intermediate compound of general formula (II) :



(II),

in which

X is Cl, Br, I, or a leaving group selected from (C_1-C_4-alkylsulfonyl)oxy, (C_1-C_4-fluoroalkylsulfonyl)oxy and (phenylsulfonyl)oxy, the phenyl present in (phenylsulfonyl)oxy being optionally substituted with one, two, three, four or five substituents, each of them independently selected from halogen, nitro, cyano, C_1-C_4-alkyl and C_1-C_4-alkoxy;

R^1 is selected from a hydrogen atom, a fluorine atom, a cyano group, a C_1-C_3-alkyl group, a C_1-C_3-haloalkyl group , and a C_1-C_3-haloalkoxy group;

R^2 is selected from a hydrogen atom, a fluorine atom;

R^4 is selected from a hydrogen atom, and a C_1-C_3-alkyl group;

to react

under transition metal catalysed coupling conditions such as Suzuki couplings, Negishi couplings, Kumada couplings, Stille couplings,

by allowing said intermediate compound of formula (II) to react with an organoboron compound selected from

a boronic acid of formula (IIIa)

$(R^x)B(OH)_2$

(IIIa),

a boronic ester of formula

$(R^x)B(OR^Y)_2$

(IIIb),

and a tetrafluoroborate salt of formula

$(R^x)BF_4$

(IIIc),

whereby

R^x is a C_1-C_6-alkyl group which is optionally substituted with one or two substituents and each substituent is independently selected from a hydroxy group, a C_1-C_4-alkoxy group, and a 3- to 7-membered heterocycloalkyl group; preferably a methyl group which is optionally substituted with a 3 to 7 membered heterocycloalkyl group;

a C_2-C_6-alkenyl group which is optionally substituted with an C_1-C_4-alkoxy group;

a C_5-C_9-cycloalkenyl group, which is optionally substituted with a hydroxy group;

a 3- to 9-membered heterocycloalkyl group, comprising one, two or three heteroatoms which are independently selected from –O-, -S-, -S(O)-, $S(O)_2$, and-NR^9-,

and said heterocycloalkyl group optionally further comprising a bridging group selected from –O-, -NR^9-, -CH_2-, -CH_2-CH_2-, -O-CH_2-, -CH_2-O-, -NR^9-CH_2-, and -CH_2-NR^9-;

and said heterocycloalkyl group is optionally substituted with one, two or three substituents and each substituent is independently selected from

a halogen atom;

a oxo(=O) group ;

a cyano group;

a hydroxy group;

a C_1-C_3-alkyl group which is optionally further substituted with a hydroxy group;

a C_1-C_3-haloalkyl group;

a C_1-C_3-alkoxy group;

a C_1-C_3-haloalkoxy group;

a $C(O)NR^5R^6$ group and

a NR^5R^6 group;

a 5- to 9-membered heterocycloalkyl group which is partially unsaturated and optionally substituted with one, two or three substituents and each substituent is independently selected from an oxo group (=O), a C_1-C_3-alkyl group, a $-C(O)NR^5R^6$ group, and a halogen atom;

an aryl group which is optionally substituted with one, two, three or four substituents and each substituent is independently selected from a halogen atom, a hydroxy group, a cyano group, a C_1-C_3-alkyl group, a C_1-C_3-haloalkyl group, a C_1-C_3-alkoxy group, a C_1-C_3-haloalkoxy group, and a NR^5R^6 group

a mono- or bicyclic heteroaryl group which is optionally substituted with one, two or three substituents and each substituent is independently selected from a halogen atom, a C_1-C_3-alkyl group, a cyano group, a C_1-C_3-haloalkyl group, a C_1-C_3-alkoxy group, a hydroxy group, and a NR^5R^6 group, with the proviso that said monocyclic heteroaryl group is not a pyridin-4-yl group;

R^y is C_1-C_6-alkyl, or the two residues R^y together are a C_2-C_6-alkylene group,

in the presence of a base, and

a palladium catalyst, which is selected from:

dichlorobis(triphenylphosphine)palladium, tetrakistriphenylphosphinepalladium(0), palladium(II) acetate/triscyclohexylphosphine, tris(dibenzylideneacetone)dipalladium, bis(diphenylphosphineferrocenyl)palladium(II) chloride, 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene(1,4-naphthoquinone)palladium dimer, allyl(chloro)(1,3-dimesityl-1,3-dihydro-2H-imidazol-2-ylidene)palladium, palladium(II) acetate/dicyclohexyl(2',4',6'-triisopropyl-biphenyl-2-yl)phosphine, [1,1-bis(diphenylphosphino)ferrocene]palladium(II) chloride monodichloromethane adduct, [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II), palladium (II) acetate and (2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II),

and, optionally, an additional ligand,

OR

said method comprising

the step B of allowing an intermediate compound of general formula (II) :



(II),

in which

R^4 has the meaning as defined *supra*,

X is F or Cl, with the proviso that if X is Cl, R^1 or R^2 can not be F; preferably X is F;

R^1 is selected from a hydrogen atom, a halogen atom, a cyano group, a C_1-C_3-alkyl group, a C_1-C_3-haloalkyl group, and a C_1-C_3-haloalkoxy group;

with the proviso that if X is Cl, R^1 can not be a fluorine atom;

R^2 is selected from a hydrogen atom and a halogen atom;

with the proviso that if X is Cl, R^2 can not be a fluorine atom;

with the further proviso that at least one of R^1 and R^2 exerts an electron withdrawing effect;

R^4 is selected from a hydrogen atom, and a C_1-C_3-alkyl group;

to react with

a corresponding amine, optionally as a free base or as a salt, such as a hydrochloride salt, selected from HNR^7R^8 and a cyclic amine featuring one N-H as a ring atom, said cyclic amine being selected from a 3- to 9-membered heterocycloalkane, a partially unsaturated 3- to 9-membered heterocyloalkane, and a heteroarene, containing one N-H as a ring atom, respectively,

in which

R^7 /R^8 are independently selected from

a hydrogen atom, with the proviso that R^7 = R^8 = hydrogen is excluded,

a C_1-C_6-alkyl group,

which is optionally substituted with one, two, three or four substituents and said substituent is independently selected from

a halogen atom,

a cyano group,

a hydoxy group,

a $C(O)NR^5R^6$ group,

a NR^5R^6 group,

a C_1-C_3-alkoxy group,

a C_3-C_7-cycloalkyl group which is optionally substituted with one or two substitutents and said subtituents are independently selected from a C_1-C_3-alkyl group, a oxo (=O) group, a hydroxy group and a C_1-C_3-hydroxyalkyl group;

a 3- to 7-membered heterocycloalkyl group which itself is optionally substituted with a C_1-C_3-alkyl group or an oxo (=O) group,

a heteroaryl group, which itself is optionally substituted with a C_1-C_3-alkyl group;

a -C_1-C_5-alkylene-O-C_1-C_5-alkyl group,

a -C_1-C_5-alkylene-S-C_1-C_5-alkyl group,

a -C_1-C_5-alkylene-NR^5-C_1-C_5-alkyl group,

a C_3-C_6-cycloalkyl group which is optionally substituted with a hydroxy group, and

a 3- to 6-membered heterocycloalkyl group which is optionally substituted with one or two substituents, said substituent independently selected from C_1-C_3-alkyl group and a hydroxy group,

a 3- to 9-membered heterocycloalkane containing one N-H as a ring atom is to be understood as a cyclic amine corresponding to a 3- to 9-membered heterocycloalkyl group as defined for R^3 *supra*, with the proviso it contains one N-H as a ring atom,

a partially unsaturated 3- to 9-membered heterocycloalkane containing one N-H as a ring atom is to be understood as a cyclic amine corresponding to a partially unsaturated 3- to 9-membered heterocycloalkyl group, as defined for R^3 *supra*, with the proviso it contains one N-H as a ring atom, and

a heteroarene containing one N-H as a ring atom is to be understood as a cyclic amine corresponding to a heteroaryl group as defined for R^3 *supra*, with the proviso it contains one N-H as a ring atom,

optionally in the presence of a base, and optionally the presence of an inert solvent, and at temperature ranging from RT to 160 °C,

OR

said method comprising

the step C of allowing an intermediate compound of general formula (II) :



(II),

in which

X is Cl, Br, I, or a leaving group selected from (C_1-C_4-alkylsulfonyl)oxy, (C_1-C_4-fluoroalkylsulfonyl)oxy and (phenylsulfonyl)oxy, the phenyl present in (phenylsulfonyl)oxy being optionally substituted with one, two, three, four or five substituents, each of them independently selected from halogen, nitro, cyano, C_1-C_4-alkyl and C_1-C_4-alkoxy;

R^1 is selected from a hydrogen atom, a fluorine atom, a cyano group, a C_1-C_3-alkyl group, a C_1-C_3-haloalkyl group , and a C_1-C_3-haloalkoxy group;

R^2 is selected from a hydrogen atom, a fluorine atom;

R^4 is selected from a hydrogen atom, and a C_1-C_3-alkyl group;

to react with

a corresponding amine, optionally as a free base or as a salt, such as a hydrochloride salt, selected from HNR^7R^8 and cyclic amine featuring one N-H as a ring atom, said cyclic amine being selected from a 3- to 9-membered heterocycloalkane, a partially unsaturated 3- to 9-membered heterocyloalkane, and a heteroarene, containing one N-H as a ring atom, respectively,

in which

R^7 /R^8 are independently selected from

a hydrogen atom, with the proviso that R^7 = R^8 = hydrogen is excluded,

a C_1-C_6-alkyl group,

which is optionally substituted with one, two, three or four substituents and said substituent is independently selected from

a halogen atom, a cyano group, a hydoxy group, a $C(O)NR^5R^6$ group, a NR^5R^6 group,

a C_1-C_3-alkoxy group,

a C_3-C_7-cycloalkyl group which is optionally substituted with one or two substitutents and said subtituents are independently selected from a C_1-C_3-alkyl group, a oxo (=O) group, a hydroxy group, and a C_1-C_3-hydroxyalkyl group;

a 3- to 7-membered heterocycloalkyl group which itself is optionally substituted with a C_1-C_3-alkyl group or an oxo (=O) group,

a heteroaryl group, which itself is optionally substituted with a C_1-C_3-alkyl group;

a -C_1-C_5-alkylene-O-C_1-C_5-alkyl group,

a -C_1-C_5-alkylene-S-C_1-C_5-alkyl group,

a -C_1-C_5-alkylene-NR^5-C_1-C_5-alkyl group,

a C_3-C_6-cycloalkyl group which is optionally substituted with a hydroxy group, and

a 3- to 6-membered heterocycloalkyl group which is optionally substituted with one or two substituents, said substituent independently selected from C_1-C_3-alkyl group and a hydroxy group,

a 3- to 9-membered heterocycloalkane containing one N-H as a ring atom is to be understood as a cyclic amine corresponding to a 3- to 9-membered heterocycloalkyl group as defined for R^3 *supra*, with the proviso it contains one N-H as a ring atom,

a partially unsaturated 3- to 9-membered heterocycloalkane containing one N-H as a ring atom is to be understood as a cyclic amine corresponding to a partially unsaturated 3- to 9-membered heterocycloalkyl group, as defined for R^3 *supra*, with the proviso it contains one N-H as a ring atom, and

a heteroarene containing one N-H as a ring atom is to be understood as a cyclic amine corresponding to a heteroaryl group as defined for R^3 *supra*, with the proviso it contains one N-H as a ring atom,

in the presence of a base, and of a palladium catalyst, a ligand, in an inert solvent, and in the presence of an inert solvent, and at a temperature ranging from 60°C to 160 °C,

in order to obtain a compound of formula (I) using one of said steps.

11. The methods of preparing a compound of general formula (I) according to claim 10, said methods comprising

for compound (II): R^1 is trifluoromethyl and R^2 is a hydrogen atom,

for step A:

Suzuki coupling conditions are used and the palladium catalyst is chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II), and the ligand is 2-(dicyclohexylphosphino)-2’,4’,6’-triisopropylbiphenyl and/or

for step B:

two residues R^y together are -$C(CH_3)_2$-$C(CH_3)_2$- to form a pinacol ester, the base is potassium carbonate or potassium acetate, and/or

for step C:

the palladium catalyst is tris(dibenzylideneacetone)dipalladium(0) and the ligand is 2-(dicyclohexylphosphino)-2',4',6'-triisopropyl-1,1'-biphenyl or 2,2'-bis(diphenylphosphino)-1,1'-binaphthalene.

12. A compound of general formula (I) according to any one of claims 1 to 9 for use in the treatment or prophylaxis of a hyperproliferative disease.

13. A pharmaceutical composition comprising a compound of general formula (I) according to any one of claims 1 to 9 and one or more pharmaceutically acceptable excipients.

14. A pharmaceutical combination comprising:

- one or more first active ingredients, in particular compounds of general formula (I) according to any one of claims 1 to 9, and
- one or more further active ingredients.

15. The use of a compound of general formula (I) according to any one of claims 1 to 9 for the preparation of a medicament for the treatment or prophylaxis of a disease, wherein the disease is a hyperproliferative disease, wherein the hyperproliferative disease is a cancer disease.

16. The use according to claim 15, wherein the cancer disease is brain cancer, breast cancer, cervical cancer, AML, lung cancer, skin cancer, esophagal carcinoma, ovarian cancer, pancreas cancer and prostate cancer.

17. Use of a compound having the structure of general formula (II):



(II),

in which R^1, R^2 and R^4 have the meaning as defined for the compound of general formula (I) according to anyone of claims 1-7 and X is a fluorine atom, a chlorine atom, a bromine atom or a iodine atom or a leaving group with the prerequisite that and if X is a chlorine atom, a bromine atom or a iodine atom then R^1 and R^2 is not chlorine, bromine or iodine, for the preparation of a compound of general formula (I) according to any one of claims 1 to 7.